Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun 6;32(23):2805-17.
doi: 10.1038/onc.2012.411. Epub 2012 Sep 24.

The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia

Affiliations
Review

The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia

S N Malek. Oncogene. .

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional chemotherapy treatment approaches. CLL as a disease entity is defined by a relatively parsimonious set of diagnostic criteria and therefore likely constitutes an umbrella term for multiple related illnesses. Of the enduring fundamental biological processes that affect the biology and clinical behavior of CLL, few are as central to the pathogenesis of CLL as recurrent acquired genomic copy number aberrations (aCNA) and recurrent gene mutations. Here, a state-of-the-art overview of the pathological anatomy of the CLL genome is presented, including detailed descriptions of the anatomy of aCNA and gene mutations. Data from SNP array profiling and large-scale sequencing of large CLL cohorts, as well as stimulated karyotyping, are discussed. This review is organized by discussions of the anatomy, underlying pathomechanisms and clinical significance of individual genomic lesions and recurrent gene mutations. Finally, gaps in knowledge regarding the biological and clinical effects of recurrent genomic aberrations or gene mutations on CLL are outlined to provide critical stimuli for future research.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Genomic copy number heatmap displays of chromosome 13q of 255 CLL cases ranked by the position of centromeric 13q14 deletion break points. (a) Copy number heatmap displays for paired DNA samples based on SNP 6.0 array profiling were generated using dChipSNP. Left panel: CD3 + or buccal DNA; right panel: CLL CD19 + DNA. Blue indicates copy loss. Each column represents one patient. (b) Schemas of various del13q14 in CLL: M, maternal chromosome; P, paternal chromosome. The approximate locations of selected genes (miR15a/16.1, DLEU7 and RB) are indicated. Deletions are indicated by blue bars.
Figure 2
Figure 2
(a) Genomic copy number heatmap displays of chromosome 17p of 255 CLL cases: copy number heatmap displays for paired DNA samples based on SNP 6.0 array profiling were generated using dChipSNP. Left panel: CD3 + or buccal DNA; right panel: CLL CD19 + DNA. Blue indicates copy loss, red indicates copy gain. Each column represents one patient. Lower panel: 17p-LOH; red arrows indicate cases with cnLOH-17p. (b) Schemas of del17p in relation to TP53 mutations and LOH at 17p in CLL: M, maternal chromosome; P, paternal chromosome. The approximate location of TP53 is indicated. Red bars indicate mutated TP53.
Figure 3
Figure 3
(a–h) Genomic copy number heatmap display of eight distinct recurrent aCNAs based on 255 CLL cases: Blue indicates copy loss, red indicates copy gain. Asterisks indicate an aCNA. Based on highly purified DNA from sorted CD19 + and CD3 + cells as described in Ouillette et al. (2011).

Similar articles

Cited by

References

    1. Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol. 2008;26:e5–e6. - PMC - PubMed
    1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916. - PubMed
    1. Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 Trial. J Clin Oncol. 2012;30:1647–1655. - PubMed
    1. Spaner DE. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia. 2012;26:1144–1145. - PubMed
    1. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994–4001. - PubMed

Publication types